Business, energy, technology, markets and global industry news from Business News Today

Werewolf Therapeutics

PharmaDeviceNews Werewolf Therapeutics
Ambros Therapeutics is valued at $500 million in an all-stock transaction paired with $150 million in financing to advance the pivotal neridronate programme through Phase 3 data and a planned FDA filing. Representative image.
Medical Devices & Diagnostics

Ambros Therapeutics takes neridronate public through Werewolf merger as $150m backs Phase 3 CRPS trial

The all-stock transaction values Ambros Therapeutics at $500 million and pairs its pivotal neridronate programme with a $150 million financing designed to fund development through Phase 3 data and an FDA filing.

Read More
A representative image illustrating Ambros Therapeutics’ neridronate CRPS-1 program as its merger with Werewolf Therapeutics and $150 million financing support the pivotal CRPS-RISE Phase 3 trial and planned FDA filing.
Pharma & Biotech

Neridronate gets $150m runway as Werewolf-Ambros merger funds pivotal CRPS-1 trial

Werewolf and Ambros secure $150m to fund neridronate through its pivotal CRPS-1 Phase 3 readout and planned FDA filing. See what is at stake.

Read More